Document is current

Article History

Received: 26 August 2025

Accepted: 3 November 2025

First Online: 12 February 2026

Declarations

:

: Milap Shah, Bethy S Hernowo, Trung Nguyen Cong, Gong Gyungyub, Irianiwati, Lu Bach Kim, Manuelito A. Madrid, Pathmanathan Rajadurai, Sunil Pasricha, Benjamin Yongcheng Tan and Tikamporn Jitpasutham declare no conflicts in this work. Rowen T. Yolo, Pichet Sampatanukul have received honorarium and travel support from AstraZeneca. Shir-Hwa Ueng has received honorarium and travel support from AstraZeneca and Discovery Life Science and serves as Council member of the Taiwan Society of Pathology, Breast Cancer Committee. Puay Hoon Tan has received honoraria and travel support from AstraZeneca and Singapore Pathology and also holds shares in Tamarind Health.

: As this was a non-interventional, physician-based Delphi consensus, formal IRB approval was not required. The study did not involve vulnerable populations, identifiable personal or clinical data, or human tissue samples; therefore, the Declaration of Helsinki also does not apply. Prior to the consensus process, participants were fully informed of the study objectives. Participation was voluntary, responses reflected independent opinions and were anonymized, and no sensitive or patient-related information was collected. All data were handled confidentially, and informed consent was obtained from all participating pathologists before initiating the virtual surveys. Participants were aware that study results would be published. All data informing the consensus guideline were sourced from publicly available information.